Doximity Inc (DOCS) Fair Value & Analysis
Healthcare · US · Market cap $4.1B · ISIN US26622P1075
What is Doximity Inc really worth?
Doximity Inc
DOCS · US
A strong business, currently priced close to our fair value of $25.91.
Strengths
Risks
Fair value as of: Aug 27, 2026
From 24 valuation models · updated 8 days ago
Share price +23.8% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- The price sits in the upper half of our model range, so the margin of safety is thin.
- The data supports the verdict: every model runs on fully documented inputs.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 27, 2026.
How to read this chart
60‑month range $18.01 – $102.02 · fair‑value band $19.83 – $31.99 · the $27.10 price screens above the $25.91 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 27, 2026.
Analysis
Doximity Inc (DOCS) currently trades at $27.10, while our model-based Fair Value estimate is $25.91, implying the stock looks roughly 4.6% fairly valued today. The Quality Score stands at 89/100 (high quality), in the Healthcare sector. Bull case: the DCF Models group reads highest at a median of $51.90 per share, and 16 of the 24 models we run sit above the $27.10 price. Bear case: the Asset-Based group reads lowest at $4.83, and 8 of the 24 models stay below the price. Evidence for this calculation is high.
Over the trailing twelve months, Doximity Inc generated revenue of $645M at a net margin of 30.4%. Revenue grew 5.1% year over year. It earns a return on equity of 19.3%. The balance sheet holds a net cash position of $209M. Fundamentals as of Aug 27, 2026
Our scenario range runs from $19.83 (bear case) to $31.99 (bull case); at $27.10, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 65% below its 52-week high and 58% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −68% fair-value upside, at −4%, DOCS screens cheaper than that median.
Fair Value models
This estimate rests on fiscal year 2026 figures, and about 5 months have passed since. In that time the company retained roughly $0.4215 per share, which is 1.6 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 24 models by family
Widest divergence: DCF Models ($51.90) versus Asset-Based ($4.83). Highest evidence: FCF DCF (74).
Notify me when DOCS reaches fair value
Put DOCS on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 27, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 87 · Market factors (momentum, volatility) 27
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Doximity, Inc. operates a digital platform for medical professionals in the United States. Its Doximity platform includes a personalized newsfeed that presents clinical and professional content to members, which offers medical articles, clinical trials or research results in an easy-to-consume video format, professional updates and accomplishments of their …
Full company description
Doximity, Inc. operates a digital platform for medical professionals in the United States. Its Doximity platform includes a personalized newsfeed that presents clinical and professional content to members, which offers medical articles, clinical trials or research results in an easy-to-consume video format, professional updates and accomplishments of their peers and colleagues, clinical discussions, Op-Med articles for publication, and sponsored content from pharmaceutical manufacturers and health systems. The company also offers workflow tools, including Ask, a HIPAA-compliant AI assistant, to access and apply evidence-based medical information within clinical workflows; Scribe, a HIPAA-compliant, AI-powered clinical documentation tool; Telehealth tools for hospitals and health systems; and AMiON, an on-call scheduling tool. The company primarily serves physicians, nurse practitioners, physician assistants, medical students, pharmaceutical manufacturers, and healthcare systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Doximity Inc reported revenue of $645M in FY2026 versus $344M in FY2022, a compound +17.0%/yr. Reported net income was $196M in FY2026, compounding +6.1%/yr from FY2022.
Watch DOCS: get an alert when its fair value changes →
Recent news
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.
- 3 Reasons to Avoid DOCS and 1 Stock to Buy Instead
- Amplitude, GitLab, Doximity, Freshworks, and Sprinklr Shares Skyrocket, What You Need To Know
- Reasons to Retain Doximity Stock in Your Portfolio for Now
Peer Group
Health Information Services · 128 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Health Information Services median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 44/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Aug 27, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Veeva Systems Inc VEEV | $282.13 | $91.49 | −68% |
| Pro Medicus Limited PME | A$183.71 | A$23.74 | −87% |
| BrightSpring Health Services, Inc BTSG | $59.68 | $21.31 | −64% |
| HealthEquity, Inc HQY | $104.27 | $56.63 | −46% |
| Hinge Health, Inc HNGE | $86.32 | $24.03 | −72% |
| 10x Genomics, Inc TXG | $55.63 | $17.18 | −69% |
| Waystar Holding WAY | $25.76 | $12.86 | −50% |
| XtalPi Holdings 2228 | HK$8.19 | HK$1.04 | −87% |
| Privia Health Group PRVA | $21.07 | $5.26 | −75% |
| IKS IKS | ₹1,785 | ₹830.74 | −53% |
Compare Doximity Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Doximity Inc (DOCS) overvalued or undervalued?
What is the fair value of DOCS?
What is the quality score of DOCS?
What is the revenue of Doximity Inc (DOCS)?
What is the net profit margin of DOCS?
Watch Doximity Inc in the live analysis
One click puts Doximity Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.